Optiscan has been featured in Stockhead's Long Shortz where Optiscan CEO Dr. Camile Farah spoke with Tylah Tully to discuss progress in the company’s breast cancer imaging study and why reaching the halfway mark is an important milestone on the path to FDA submissions.

Dr Farah outlines how the study supports Optiscan’s InVue and InForm platforms, upcoming clinical programs, and the key catalysts investors can expect over the next six months.

Watch the full episode here.